Thiopental
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Using no additional skill — this is a direct report-drafting task per the loaded prompt template; proceeding directly.
Thiopental: From General Anesthesia Induction to Trichotillomania
One-Sentence Summary
Thiopental is a classic ultra-short-acting barbiturate historically used for intravenous induction of general anesthesia (and, off-label, for barbiturate coma in refractory status epilepticus). The TxGNN model predicts it may be relevant to Trichotillomania, but this signal currently has 0 clinical trials and 0 publications in support — it is a pure model-generated hypothesis with no empirical or mechanistic backing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved-indication text available in the regulatory dataset (drug not marketed in India); classically used as an ultra-short-acting IV anesthetic induction agent (barbiturate class) |
| Predicted New Indication | Trichotillomania |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not directly available for this drug in the evidence pack (flagged as a High-severity data gap). However, cross-referencing the rationale text attached to other predicted indications in this same evidence pack confirms Thiopental acts as a GABA-A receptor positive allosteric modulator, the standard mechanism underlying barbiturate sedative-hypnotic and anesthetic effects.
Trichotillomania (compulsive hair-pulling disorder) is currently understood primarily through dysregulation of glutamatergic and serotonergic/dopaminergic circuits, and treatment research has focused on agents like N-acetylcysteine, SSRIs, and glutamate modulators — not GABA-A potentiators. The evidence pack itself is explicit on this point: “no known mechanistic link connects trichotillomania to GABA-A receptor modulation; this is a pure model prediction with no supporting data.”
In other words, the high TxGNN score reflects graph-embedding proximity in the knowledge graph, not a validated pharmacological rationale. This prediction should be treated as a hypothesis-generating signal only, not as evidence of plausible clinical benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Thiopental has no regulatory license records in the current dataset — market status is “Not Marketed” with 0 total registrations. No authorization number, product name, dosage form, or approved indication text is available for India.
Safety Considerations
Structured key-warning and contraindication text is not available in this dataset (regulatory label data collection is listed as a Blocking data gap — TFDA/label PDF not yet retrieved/parsed). Please refer to the official package insert for warnings and contraindications.
Drug Interactions (from DDInter; 20 of 45 total documented interactions shown):
| Interacting Drug | Severity |
|---|---|
| Ethanol | Major |
| Warfarin | Major |
| Doxycycline | Moderate |
| Morphine | Moderate |
| Dronabinol | Moderate |
| Nabilone | Moderate |
| Nitisinone | Moderate |
| Methylene blue | Moderate |
| Iodide I-131 | Moderate |
| Iodide I-123 | Moderate |
| Codeine | Moderate |
| Cetirizine | Moderate |
| Hydrocodone | Moderate |
| Dextromethorphan | Moderate |
| Carbinoxamine | Moderate |
| Clemastine | Moderate |
| Pyridoxine | Minor |
| Cimetidine | Minor |
| Sulfasalazine | Minor |
| Promethazine | Minor |
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (Trichotillomania) has no clinical trial or literature support and no plausible mechanistic link per the evidence pack itself — it is a model-only signal (L5, Decision Stage S0). Combined with a Blocking-severity gap in regulatory label/safety data, this candidate cannot currently pass an S1 safety screen.
To proceed, the following is needed:
- TFDA/Indian product label (warnings, contraindications) to close the Blocking data gap (DG001)
- Confirmed mechanism-of-action data from DrugBank (DG002)
- Independent mechanistic or preclinical rationale connecting GABA-A modulation to trichotillomania before any further evidence collection is warranted
Note: Among the other 9 candidates in this evidence pack, frontal lobe epilepsy (rank 2) shows comparatively stronger — though still preliminary — support (L4, “Research Question” stage, tied to the known off-label use of thiopental-induced barbiturate coma in refractory status epilepticus) and may be a more productive avenue than the top-ranked trichotillomania signal.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.